Drug intelligence / Profile preview

NOBO-301

Development stage: Preclinical
Lead developer: NOBO Medicine
Modality: Small Molecules

Overview

NOBO-301 is a small molecule caspase inhibitor currently in preclinical development by NOBO Medicine. It is part of the company's proprietary NOBO-VERSE platform and is being investigated for the treatment of hemato-inflammatory diseases. Caspases are a family of protease enzymes that are critical mediators of apoptosis and inflammatory signaling. By targeting these enzymes, NOBO-301 aims to regulate pathological cell death and inflammation associated with hematological disorders. This program is distinct from NOBO Medicine's more advanced caspase inhibitor, NOBO-101 (Emricasan).

Targets

CASP (Caspase family)

Beyond the preview

Go deeper on NOBO-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NOBO-301.

Explore the full profile